The delisting risk is removed, which should provide a floor for the stock in the near term. However, the 12-month probationary period means any future financial or compliance misstep could trigger expedited delisting. Monitor upcoming quarterly filings for signs of financial deterioration that could trigger a second noncompliance event.
Price Chart
Executive Summary
Azitra (AZTR) announced it has regained compliance with NYSE American continued listing standards, resolving previously disclosed deficiencies under Sections 1003(a)(ii) and (iii) of the Company Guide. The .BC indicator will be removed from its trading symbol, and the company will be taken off the NYSE American noncompliant issuers list. This removes the immediate delisting risk but the company remains under continued listing monitoring and faces a 12-month probationary period where a second noncompliance could trigger expedited delisting proceedings.
Key Facts
- Azitra received a letter from NYSE Regulation dated August 19, 2026, confirming regained compliance with all NYSE American continued listing standards.
- The company resolved deficiencies under Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide.
- The .BC (below compliance) indicator will be removed from the AZTR trading symbol.
- Azitra will be removed from NYSE American's list of noncompliant issuers.
- If the company is again found noncompliant within 12 months, NYSE American may truncate compliance procedures or immediately initiate delisting proceedings.
Financial Impact
No financial figures provided in the filing. The event removes delisting risk for an $8M market cap company.
Risk Factors
- If Azitra falls below continued listing standards again within 12 months, NYSE American may immediately initiate delisting proceedings.
- The company remains a clinical-stage biopharma with no approved products and an $8M market cap, leaving it vulnerable to future listing issues if it cannot raise capital or advance its pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-039565 |
| Exhibit: ex99-1.htm | 0001493152-26-039565 |
| Document: 0001493152-26-039565-index-headers.html | 0001493152-26-039565 |
| Document: 0001493152-26-039565-index.html | 0001493152-26-039565 |
| Document: 0001493152-26-039565.txt | 0001493152-26-039565 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.04 | awaiting T+1 | — | $1.53 (+47.12%) |
Oct 22, 2026 4d ago | 8-K | $0.0715 $0.1530 | ▲ +113.99% | ▲ +113.28% | $1.53 (+2039.86%) |
Oct 1, 2026 25d ago | 8-K | $0.1285 $0.1320 | ▲ +2.72% | ▲ +1.98% | $1.53 (+1090.66%) |
Aug 21, 2026 9w ago | 8-K | $0.1328 $0.1504 | ▲ +13.25% | ▲ +13.55% | $1.53 (+1052.11%) |
Aug 12, 2026 10w ago | Press Release | $0.1400 $0.1393 | ▲ +0.50% | ▲ +0.30% | $1.53 (−992.86%) |
Jun 17, 2026 18w ago | 8-K | $0.2030 $0.1717 | ▼ −15.42% | ▼ −16.20% | $1.53 (+653.69%) |
Jun 3, 2026 20w ago | EFFECT | $0.2240 $0.2180 | ▲ +2.68% | ▲ +3.08% | $1.53 (−583.04%) |
May 21, 2026 22w ago | S-1 | $0.2040 $0.2100 | ▼ −2.94% | ▼ −2.36% | $1.53 (−650.00%) |
Mar 5, 2026 33w ago | 8-K | $0.1800 $0.2030 | ▲ +12.78% | ▲ +11.93% | $1.53 (+750.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers